NCT01741831View on ClinicalTrials.gov

A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista

CompletedOBSERVATIONAL

Enrollment

225

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions

Acquired Immune Deficiency Syndrome

Interventions

DRUG

No intervention

This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally for a period of 24 weeks. For treatment naive (never received treatment for AIDS) patients: Darunavir 800 mg will be adminstered along with ritonavir 100 mg once daily. For experienced patients: Darunavir 600 mg will be administered along with ritonavir 100 mg twice daily.

Trial Locations (1)

Unknown

Daegu

All Listed Sponsors

lead

Janssen Korea, Ltd., Korea

INDUSTRY

NCT01741831 - A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista | Biotech Hunter | Biotech Hunter